
BMY
Bristol-Myers Squibb Company
$47.18
+$0.30(+0.64%)
67
Overall
95
Value
40
Tech
--
Quality
Market Cap
$96.09B
Volume
10.69M
52W Range
$42.96 - $63.33
Target Price
$52.29
Order:
Income Statement
Metric | Trend | Chart | 2015 Dec | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||
Total Revenue | $33.1B | $38.9B | $20.8B | $22.6B | $26.1B | $42.5B | $46.4B | $46.2B | $45.0B | $48.3B | ||
Total Revenue | $16.6B | $19.4B | $20.8B | $22.6B | $26.1B | $42.5B | $46.4B | $46.2B | $45.0B | $48.3B | ||
COST OF GOODS SOLD | ||||||||||||
Cost of Revenue | $3.9B | $4.9B | $6.1B | $6.5B | $8.1B | $11.8B | $9.9B | $10.1B | $10.7B | $14.0B | ||
GROSS PROFIT | ||||||||||||
Gross Profit | $12.7B | $14.5B | $14.7B | $16.1B | $18.1B | $30.7B | $36.4B | $36.0B | $34.3B | $34.3B | ||
OPERATING EXPENSES | ||||||||||||
Operating Expenses | $10.8B | $9.9B | $11.2B | $10.9B | $15.5B | $18.8B | $17.9B | $26.9B | $17.1B | $19.6B | ||
Research & Development | $5.9B | $4.9B | $6.5B | $6.3B | $6.1B | $11.1B | $10.2B | $9.5B | $9.3B | $11.2B | ||
Research Expense | $5.9B | $4.9B | $6.5B | $6.3B | $6.1B | $11.1B | $10.2B | $9.5B | $9.3B | $11.2B | ||
Selling, General & Administrative | $4.8B | $4.9B | $4.8B | $4.6B | $4.9B | $7.7B | $7.7B | $7.8B | $7.8B | $8.4B | ||
Selling & Marketing Expenses | $825.0M | $789.0M | $740.0M | $672.0M | $633.0M | $990.0M | $1.3B | $1.3B | $1.4B | $1.5B | ||
General & Administrative Expenses | $4.8B | $4.9B | $4.8B | $4.6B | $4.9B | $7.7B | $7.7B | $7.8B | $7.8B | $8.4B | ||
Salaries & Wages | $-77.0M | $-69.0M | $-59.0M | $-41.0M | $-87.0M | $-158.0M | $-120.0M | $-91.0M | $-105.0M | $-108.0M | ||
Depreciation & Amortization | $500.0M | $448.0M | $682.0M | $505.0M | $554.0M | $586.0M | $559.0M | $587.0M | $611.0M | $651.0M | ||
Depreciation & Amortization | $500.0M | $448.0M | $682.0M | $505.0M | $554.0M | $586.0M | $559.0M | $587.0M | $611.0M | $651.0M | ||
Amortization | $6.9B | $6.9B | $6.9B | $6.5B | $64.0B | $53.3B | $42.5B | $35.9B | $27.1B | $23.3B | ||
Other Operating Expenses | $-52.0M | $-49.0M | $-173.0M | $-48.0M | $-170.0M | $-76.0M | $-66.0M | $-53.0M | $-38.0M | $-68.0M | ||
OPERATING INCOME | ||||||||||||
Operating income | $18.4B | $24.1B | $3.4B | $5.3B | $21.8B | $33.1B | $29.7B | $18.7B | $17.2B | $14.8B | ||
EBITDA | $2.7B | $6.4B | $6.1B | $6.8B | $8.7B | $4.9B | $20.1B | $19.2B | $18.2B | $20.0B | ||
NON-OPERATING ITEMS | ||||||||||||
Interest Expense (Non-Operating) | $184.0M | $167.0M | $196.0M | $183.0M | $656.0M | $1.4B | $1.3B | $1.2B | $1.2B | -- | ||
Intinc | $101.0M | $105.0M | $126.0M | $173.0M | $464.0M | $121.0M | $39.0M | $171.0M | $449.0M | $478.0M | ||
Net Non-Operating Interest Income/Expense | $-83.0M | $-62.0M | $-70.0M | $-10.0M | $-192.0M | $-1.3B | $-1.3B | $1.2B | $449.0M | $478.0M | ||
Gain on Sale of Securities | -- | $-45.0M | $23.0M | $7.0M | $275.0M | $1.2B | $745.0M | $17.0M | $3.0M | $16.0M | ||
Other Income/Expense | $-187.0M | $-1.3B | $-1.7B | $-854.0M | $938.0M | $-2.3B | $-720.0M | $-159.0M | $-1.2B | $893.0M | ||
Other Special Charges | $187.0M | $1.3B | $1.7B | $854.0M | $-938.0M | $2.3B | $720.0M | $-576.0M | $1.2B | $-893.0M | ||
SPECIAL ITEMS | ||||||||||||
Restructring And Mn A Income | $-15.0M | $213.0M | $-319.0M | $4.1B | $-3.4B | $-10.0M | $-19.0M | $-7.0M | $777.0M | $1.1B | ||
Special Income Charges | $-157.0M | $-275.0M | $806.0M | $-4.2B | $3.3B | $183.0M | $-63.0M | $-171.0M | $-387.0M | $-1.2B | ||
Impairment of Capital Assets | $13.0M | $15.0M | $241.0M | $64.0M | $15.0M | $21.0M | -- | -- | -- | -- | ||
PRE-TAX INCOME | ||||||||||||
EBIT | $2.1B | $5.9B | $5.1B | $5.9B | $5.2B | $-5.5B | $9.4B | $8.9B | $8.4B | $9.7B | ||
Pre-Tax Income | $2.1B | $5.9B | $5.1B | $6.0B | $5.0B | $-6.9B | $8.1B | $7.7B | $8.4B | $-8.4B | ||
INCOME TAX | ||||||||||||
Tax Provision | $446.0M | $1.4B | $4.2B | $1.0B | $1.5B | $2.1B | $1.1B | $1.4B | $400.0M | $554.0M | ||
NET INCOME | ||||||||||||
Net Income | $1.6B | $4.5B | $1.0B | $4.9B | $3.4B | $-9.0B | $7.0B | $6.3B | $8.0B | $-8.9B | ||
Net Income (Continuing Operations) | $1.6B | $4.5B | $1.0B | $4.9B | $3.4B | $-9.0B | $7.0B | $6.3B | $8.0B | $-8.9B | ||
Net Income (Discontinued Operations) | $1.6B | $4.5B | $1.0B | $4.9B | $3.4B | $-9.0B | $7.0B | $6.3B | $8.0B | $-8.9B | ||
Net Income (Common Stockholders) | $18.1B | $23.9B | $1.0B | $10.1B | $19.3B | $-9.0B | $7.0B | $6.3B | $8.0B | $-8.9B | ||
Normalized Income | $1.7B | $4.2B | $2.6B | $-27.2B | $-38.5B | $-6.3B | -- | -- | -- | $-3.9B | ||
TOTALS | ||||||||||||
Total Expenses | $14.7B | $14.8B | $17.3B | $17.4B | $23.6B | $30.6B | $27.8B | $37.1B | $27.8B | $33.5B | ||
SHARE & EPS DATA | ||||||||||||
Average Shares Outstanding | $1.7B | $1.7B | $1.6B | $1.6B | $1.7B | $2.3B | $2.2B | $2.1B | $2.1B | $2.0B | ||
Average Shares Outstanding (Diluted) | $1.7B | $1.7B | $1.7B | $1.6B | $1.7B | $2.3B | $2.2B | $2.1B | $2.1B | $2.0B | ||
Shares Outstanding | $1.7B | $1.7B | $1.6B | $1.6B | $2.3B | $2.2B | $2.2B | $2.1B | $2.0B | $2.0B | ||
Basic EPS | $0.94 | $2.67 | $0.61 | $3.01 | $2.02 | $-3.99 | $3.15 | $2.97 | $3.88 | $-4.41 | ||
Basic EPS (Continuing Operations) | $0.94 | $2.67 | $0.61 | $3.01 | $2.02 | $-3.99 | $3.15 | $2.97 | $3.88 | $-4.41 | ||
Diluted EPS | $0.93 | $2.65 | $0.61 | $3.01 | $2.01 | $-3.99 | $3.12 | $2.95 | $3.86 | $-4.41 | ||
Diluted EPS (Continuing Operations) | $0.93 | $2.65 | $0.61 | $3.01 | $2.01 | $-3.99 | $3.12 | $2.95 | $3.86 | $-4.41 | ||
Dividend Per Share | $1.49 | $1.53 | $1.57 | $1.61 | $1.68 | $1.84 | $2.01 | $2.19 | $2.31 | $2.42 | ||
OTHER METRICS | ||||||||||||
Acquisition Expense | -- | -- | -- | -- | $657.0M | -- | -- | -- | -- | -- | ||
Commission Expenses | -- | -- | -- | -- | -- | $24.4B | -- | -- | -- | -- | ||
Earnings from equity interest | $83.0M | $77.0M | $75.0M | $93.0M | $-4.0M | $72.0M | $231.0M | $-108.0M | $-38.0M | $44.0M | ||
Earnings From Equity Interest Net Of Tax | $83.0M | $77.0M | $75.0M | $93.0M | $-4.0M | $72.0M | $231.0M | $-108.0M | $-38.0M | $44.0M | ||
Gains Loss On Disposal Of Discontinued Operations | $194.0M | $564.0M | $164.0M | $178.0M | $1.2B | $55.0M | $9.0M | $211.0M | -- | $-15.0M | ||
Interest Expense Operating | $-205.0M | $-191.0M | $-215.0M | $-218.0M | $-414.0M | $-1.6B | $-1.5B | $-1.4B | $-1.2B | $-1.8B | ||
Marketing Expense | $825.0M | $789.0M | $740.0M | $672.0M | $633.0M | $990.0M | $1.3B | $1.3B | $1.4B | $1.5B | ||
Minority Interests | $-66.0M | $-50.0M | $32.0M | $-27.0M | $-21.0M | $-20.0M | $-20.0M | $-18.0M | $-15.0M | -- | ||
Net Income Discontinuous Operations | $194.0M | $564.0M | $164.0M | $178.0M | $1.2B | $55.0M | $9.0M | $211.0M | -- | $-15.0M | ||
Net Income Extraordinary | -- | -- | -- | $4.9B | $3.5B | -- | -- | -- | -- | -- | ||
Non Recurring Operation Expense | $159.0M | $47.0M | $-487.0M | $76.0M | $77.0M | $-194.0M | $82.0M | $178.0M | $-390.0M | $84.0M | ||
Other Gand A | $4.8B | $4.9B | $4.8B | $4.6B | $4.9B | $7.7B | $7.7B | $7.8B | $7.8B | $8.4B | ||
Other Impairment Of Capital Assets | $181.0M | $33.0M | $80.0M | $84.0M | $-27.0M | $1.1B | $1.2B | $101.0M | $136.0M | $2.9B | ||
Other Taxes | -- | -- | -- | -- | $4.5B | -- | -- | -- | -- | -- | ||
Other Write Off | -- | -- | $-3.0M | -- | -- | -- | -- | -- | -- | -- | ||
Rent And Landing Fees | $140.0M | $145.0M | $120.0M | $130.0M | -- | -- | -- | -- | -- | -- | ||
Restruct | $-15.0M | $213.0M | $-319.0M | $4.1B | $-3.4B | $-10.0M | $-19.0M | $-7.0M | $777.0M | $1.1B |
Financial data is updated quarterly and may not reflect the most recent earnings.
A | B | C | D | |
---|---|---|---|---|
1 | Symbol | Price | Change | Vol |
2 | BMY | $47.18 | +0.6% | 10.69M |
3 | ||||
4 | ||||
5 | ||||
6 |
Get Bristol-Myers Squibb Company Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW